Opinion|Videos|May 20, 2025
The Use of PARP Inhibitors in Ovarian Cancer
Author(s)Kathleen Moore, MD, MS
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.
Advertisement
Episodes in this series
Video content is prompted by the following:
PARP Inhibitors in Ovarian Cancer Treatment
Key Themes:
- Biomarker-directed PARP inhibitor use in frontline treatment
- Current FDA approvals and indications
- Overall survival concerns in platinum-sensitive settings
Notable Insights:
- Current frontline approvals:
- Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum
- Olaparib with bevacizumab for HRD-positive tumors
- Niraparib approved for all-comers whose tumors responded to chemotherapy
- Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
- The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.
Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use them is in frontline...there is the chance we are curing more patients. We believe that.”
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
5